Table 4.

AEs occurring in ≥10% of patients and AEs of special interest occurring during treatment with riociguat

	Full analysis set (n = 300)	Incidence per 100 patient-years
AE, n (%)
Dyspepsia	60 (20)	27.5
Dizziness	56 (19)	26.0
Headache	54 (18)	29.4
Peripheral edema	54 (18)	23.0
Diarrhea	45 (15)	20.0
Nausea	43 (14)	18.8
Cough	38 (13)	16.6
Vomiting	34 (11)	16.6
Hypotension	29 (10)	12.4
Constipation	31 (10)	13.6
Gastroesophageal reflux disease	31 (10)	12.8
Nasopharyngitis	31 (10)	14.7
AE of special interest, n (%)
Pre-syncope	10 (3)	4.1
Syncope	17 (6)	9.8

AE adverse event